Sigma Planning Corp Has $231,000 Holdings in Boston Scientific Co. (NYSE:BSX)

Sigma Planning Corp cut its stake in Boston Scientific Co. (NYSE:BSX) by 60.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,991 shares of the medical equipment provider’s stock after selling 6,222 shares during the period. Sigma Planning Corp’s holdings in Boston Scientific were worth $231,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BSX. Harbor Capital Advisors Inc. raised its holdings in shares of Boston Scientific by 0.8% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 50,024 shares of the medical equipment provider’s stock worth $2,641,000 after buying an additional 409 shares in the last quarter. PDS Planning Inc grew its position in Boston Scientific by 9.3% during the 3rd quarter. PDS Planning Inc now owns 4,468 shares of the medical equipment provider’s stock worth $236,000 after acquiring an additional 379 shares during the last quarter. Cavalier Investments LLC grew its position in Boston Scientific by 56.0% during the 3rd quarter. Cavalier Investments LLC now owns 60,193 shares of the medical equipment provider’s stock worth $3,178,000 after acquiring an additional 21,615 shares during the last quarter. Commonwealth Equity Services LLC grew its position in Boston Scientific by 7.0% during the 3rd quarter. Commonwealth Equity Services LLC now owns 201,364 shares of the medical equipment provider’s stock worth $10,632,000 after acquiring an additional 13,121 shares during the last quarter. Finally, FAS Wealth Partners Inc. grew its position in Boston Scientific by 4.2% during the 3rd quarter. FAS Wealth Partners Inc. now owns 7,129 shares of the medical equipment provider’s stock worth $376,000 after acquiring an additional 285 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

NYSE:BSX opened at $73.17 on Monday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.82 and a current ratio of 1.32. The stock’s 50-day simple moving average is $67.82 and its 200 day simple moving average is $60.63. The company has a market cap of $107.35 billion, a P/E ratio of 61.49, a P/E/G ratio of 2.51 and a beta of 0.78. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $74.39.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. During the same quarter in the previous year, the business earned $0.45 earnings per share. As a group, sell-side analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the sale, the executive vice president now owns 50,638 shares of the company’s stock, valued at $3,509,213.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,979 shares of company stock worth $3,418,529. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on BSX shares. Needham & Company LLC increased their price target on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Oppenheimer increased their price objective on Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a research report on Thursday, February 1st. Raymond James increased their price objective on Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research report on Thursday. StockNews.com lowered Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Finally, Barclays increased their price objective on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.